What’s Next? Five Things To Look Out For In March
Bristol Myers Squibb Braces For US Impact To Revlimid And Abraxane
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.
